You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis

 

Online download statistics by month:

Online download statistics by month: January 2020 to August 2024

AbstractFullPdf
Jan 2020439439142
Feb 202027827878
Mar 202019919955
Apr 202014414420
May 2020999917
Jun 202089899
Jul 2020686834
Aug 2020404011
Sep 202010310328
Oct 2020757536
Nov 2020464619
Dec 2020656524
Jan 2021757531
Feb 2021616128
Mar 202110110131
Apr 202110210220
May 202110210245
Jun 2021787825
Jul 2021949433
Aug 2021858520
Sep 2021808024
Oct 2021535341
Nov 2021636335
Dec 2021586033
Jan 2022424522
Feb 2022343415
Mar 2022363722
Apr 2022414516
May 2022535321
Jun 2022576046
Jul 2022525412
Aug 2022333314
Sep 2022454626
Oct 2022515127
Nov 2022485034
Dec 2022363617
Jan 2023444528
Feb 2023727326
Mar 2023798020
Apr 2023414119
May 2023313118
Jun 2023323312
Jul 2023393918
Aug 202318189
Sep 202326267
Oct 2023262622
Nov 202325258
Dec 2023343417
Jan 2024454630
Feb 2024303016
Mar 2024555582
Apr 202412012124
May 2024313117
Jun 2024333320
Jul 2024414214
Aug 2024171754
Total396439891572